Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 2/20 | 0.83 |
| ▸ | CA9 | Q16790 | 4/20 | 0.77 |
| ▸ | SLC10A1 | Q14973 | 2/20 | 0.75 |
| ▸ | NT5E | P21589 | 3/20 | 0.73 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.73 |
| ▸ | USP2 | O75604 | 1/20 | 0.73 |
| ▸ | LMNA | P02545 | 1/20 | 0.73 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.73 |
| ▸ | TOP2A | P11388 | 1/20 | 0.73 |
| ▸ | RELA | Q04206 | 1/20 | 0.73 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.64 |
| ▸ | CA1 | P00915 | 1/20 | 0.64 |
| ▸ | CA2 | P00918 | 1/20 | 0.64 |
| ▸ | CETP | P11597 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL214200 | 1.00 | PTGES (0.83) | PTGESCA9SLC10A1NT5EPTPN1 | |
| SCHEMBL14345008 | 1.00 | PTGES (0.83) | PTGESCA9SLC10A1NT5EPTPN1 | |
| SCHEMBL6112807 | 1.00 | PTGES (0.83) | PTGESCA9SLC10A1NT5EPTPN1 | |
| SCHEMBL10214430 | 1.00 | PTGES (0.83) | PTGESCA9SLC10A1NT5EPTPN1 | |
| Water SCHEMBL8584387 | 0.99 | PTGES (0.82) | PTGESCA9SLC10A1NT5EPTPN1 | |
| Ether SCHEMBL8586168 | 0.96 | PTGES (0.78) | PTGESCA9SLC10A1NT5EPTPN1 | |
| SCHEMBL13855630 | 0.93 | PTGES (0.72) | PTGESCA9SLC10A1NT5EPTPN1 | |
| SCHEMBL5454249 | 0.93 | NT5E (0.75) | PTGESCA9SLC10A1NT5EPTPN1 | |
| SCHEMBL13573803 | 0.93 | NT5E (0.75) | PTGESCA9SLC10A1NT5EPTPN1 | |
| SCHEMBL5956476 | 0.92 | PTGES (0.74) | PTGESCA9SLC10A1NT5EPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088757-B2 | Betulinol derivatives as anti-cancer agents | BIORINGS LLC (US) | 2012-01-03 | — | — | US | disclosed |
| US-8008280-B2 | Betulinol derivatives as anti-HIV agents | BIORINGS LLC (US) | 2011-08-30 | — | — | US | disclosed |
| US-20090176753-A1 | Betulinol derivatives as anti-cancer agents | SAXENA RESEARCH, LLC | 2009-07-09 | — | — | US | disclosed |
| US-20080286291-A1 | Betulinol Derivatives as Anti-Hiv Agents | SAXENA RESEARCH, LLC | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176753-A1 | Betulinol derivatives as anti-cancer agents | BET1, BRDT, BRCA1 | PTGES 2093/4885CA9 270/4885SLC10A1 2305/4885 |
| US-20080286291-A1 | Betulinol Derivatives as Anti-Hiv Agents | BET1, NFATC1, CD4 | PTGES 3919/4885CA9 2991/4885SLC10A1 649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.